Bio Innovation is
Our Mission
We are a pharmaceutical biotechnology company focusing on antibody and bacteriophage therapies to address unmet medical needs.
Our cutting-edge research aims to develop novel treatments for resistant infections and complex diseases, providing new hope for patients.
Diabetic
Retinophaty
Ocular Surface Infection
Diabetic Foot
Infection
Atopic
Dermatitis
Respiratory
Infection
Our Goals
.jpeg)
.jpeg)
Our Technology
Our advanced technology platform is driving innovation in antibody and bacteriophage therapies to meet critical unmet medical needs. By leveraging the precision of engineered antibodies and the unique capabilities of bacteriophages, we are developing targeted treatments to resistant infections and complex diseases.
Our technologies enable us to design highly specific, effective, and safe therapeutic solutions, pushing the boundaries of modern medicine and transforming patient care.
Welcome to Lxbio, where the future of biopharmaceuticals is being redefined. As a newly established pharmaceutical company, we present a compelling opportunity for investors seeking to be at the forefront of groundbreaking innovation in the global biopharmaceutical market.
Invest with us
News
LxBio is officially a member of PhageEU, a Brussels-based coalition that aims to raise the potential of phages in Europe, representing this innovative solution in industry, the scientific community and civil society.
The main mission of this team, which LxBio proudly joins as a Portuguese company, is to democratize access to phage technology in the European Union, strengthening the community who works in both industry and academia on phage services and products.
(1)_edited.png)
We are thrilled to announce the location of our new state-of-the-art biotechnology manufacturing facility and new R&D site, a significant milestone in our journey towards redefining the landscape of biotechnological innovation.
Technophage , founding partner of Lxbio Pharmaceuticals, has attended to ECCMID 2023. Together with the clinical team from Israel, it was presented the results obtained in the Phase I/IIa, aimed to determine the safety and tolerability of multiple doses of TP-102 in subjects with uninfected and infected diabetic foot ulcers. It has been successfully concluded and the company is now preparing the next clinical phases.